Atsushi Hayashi

5PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityFood properties (incl. characteristics and health benefits)Microbial ecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 28, 2024
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.

Hedyeh Ebrahimi, Nazli Dizman, Luis Meza

|Mar 02, 2024
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation.

Kentaro Fukushima, Hayami Kudo, Kentaro Oka

|Feb 22, 2024
The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt+Treg and PD-1 blockade efficacy.

Thomas Paz Del Socorro, Kentaro Oka, Olivier Boulard

|Feb 18, 2021
The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine-Dependent but GPR43/109a-Independent Mechanisms.

Atsushi Hayashi, Hiroko Nagao-Kitamoto, Sho Kitamoto

|Oct 07, 2020
Lipopolysaccharide O structure of adherent and invasive Escherichia coli regulates intestinal inflammation via complement C3.

Masashi Ohno, Mizuho Hasegawa, Atsushi Hayashi

Pageof 1

Frequent Collaborators

1 joint publications

Masashi Ohno

1 joint publications

Mizuho Hasegawa

1 joint publications

Christopher J Alteri

1 joint publications

Nobuhiko Kamada